Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.

Breast cancer research : BCR - 20 Dec 2010

Ingle James N

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstadienes
Share to Antineoplastic Agents
Share to Aromatase Inhibitors
Share to Interleukin-17

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Musculoskeletal Diseases

Share to Nitriles

Share to Pharmacogenetics

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 21172079
DOI: 10.1186/bcr2746
PMCID: PMC3005737

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.PMID 21172079Read ↗

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.Semantic proximity Read ↗

Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.Semantic proximity Read ↗

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.Semantic proximity Read ↗

Genetic prediction of long-term effects of aromatase inhibition on cancer and non-neoplastic disease riskSemantic proximity Read ↗

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.Semantic proximity Read ↗

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.Semantic proximity Read ↗

Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.Semantic proximity Read ↗

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Semantic proximity Read ↗

Re: a genome-wide association study of early menopause and the combined impact of identified variants.Semantic proximity Read ↗

No Evidence of Genotype‒Treatment Interactions between Endocrine Therapies and Adverse Drug Effects in Women with Breast Cancer: Findings from the UK BiobankSemantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.